Tomas Yeo

发表

Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors

David M. Shackleford, D. Fidock, Laura M Sanz, 2021, ACS infectious diseases.

Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in Plasmodium falciparum.

E. Winzeler, D. Fidock, M. Phillips, 2021, Journal of medicinal chemistry.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Richard D. Taylor, D. Goldberg, A. Cowman, 2022, Journal of medicinal chemistry.

A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin

K. Kirk, Adele M. Lehane, G. V. van Dooren, 2022, Nature Communications.

Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum

E. Winzeler, R. Pearson, D. Fidock, 2022, bioRxiv.

A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine

E. Winzeler, T. Egan, Jill M Combrinck, 2017, mBio.

Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine

D. Fidock, L. Ross, Satish K. Dhingra, 2018, Nature Communications.

Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness

D. Fidock, Satish K. Dhingra, Jennifer Small-Saunders, 2019, mBio.

Artemisinin-resistant K13 mutations rewire Plasmodium falciparum’s intra-erythrocytic metabolic program to enhance survival

Zbynek Bozdech, M. Llinás, D. Fidock, 2021, Nature Communications.

Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance

D. Kwiatkowski, Zbynek Bozdech, P. Newton, 2015, Science.

The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance

E. Winzeler, K. Chibale, E. Istvan, 2021, Cell Chemical Biology.

Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites

R. F. Campbell, E. Winzeler, S. Meister, 2021, Scientific Reports.

P. falciparum K13 mutations present varying degrees of artemisinin resistance and reduced fitness in African parasites

P. Rosenthal, D. Fidock, L. Ross, 2021, bioRxiv.

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4

A. Cowman, Adele M. Lehane, D. Fidock, 2023, Journal of medicinal chemistry.

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

R. Price, P. Rosenthal, D. Fidock, 2021, Science Translational Medicine.

Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

D. Fidock, L. Ross, F. Nosten, 2021, eLife.

Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity

E. Winzeler, M. Bösche, K. Chibale, 2020, Cell chemical biology.

Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation

Victoria C. Corey, E. Winzeler, D. Wirth, 2023, Nature Communications.

The antimalarial natural product salinipostin A identifies essential α/β serine hydrolases involved in lipid metabolism in P. falciparum parasites

Roger G. Linington, Kenji L. Kurita, M. Bogyo, 2019, bioRxiv.

Comparative Analysis of Plasmodium falciparum Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing

D. Fidock, P. Rosenthal, Victor Asua, 2021, Antimicrobial agents and chemotherapy.

Plasmodium falciparum K13 mutations in Africa and Asia present varying degrees of artemisinin resistance and an elevated fitness cost in African parasites

P. Rosenthal, D. Fidock, L. Ross, 2021, bioRxiv.

Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages

I. Albert, M. Llinás, D. Fidock, 2022, PLoS pathogens.

3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting Plasmodium falciparum.

D. Fidock, B. Mordmüller, John Okombo, 2021, Journal of medicinal chemistry.

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome

H. Zhang, M. Bogyo, D. Fidock, 2023, Cell chemical biology.

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

P. Rosenthal, M. Llinás, D. Fidock, 2021, bioRxiv.

Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome

E. Winzeler, L. Tilley, D. Fidock, 2021, Proceedings of the National Academy of Sciences.

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.

J. McCarthy, D. Fidock, J. Möhrle, 2022, The Lancet. Infectious diseases.

Mapping the genomic landscape of multidrug resistance in Plasmodium falciparum and its impact on parasite fitness

D. Fidock, L. Ross, P. Sinnis, 2023, bioRxiv.

Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.

David M. Shackleford, E. Winzeler, P. Rathod, 2021, Journal of medicinal chemistry.

Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase

Derek S. Tan, E. Winzeler, E. Istvan, 2023, Research Square.

Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance

D. Kwiatkowski, Zbynek Bozdech, P. Newton, 2015, Science.

Mapping the genomic landscape of multidrug resistance in Plasmodium falciparum and its impact on parasite fitness

D. Fidock, P. Sinnis, Jonathan Kim, 2023, Science advances.

Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts.

E. Winzeler, K. Chibale, Dale Taylor, 2021, Journal of medicinal chemistry.

Exploring a Tetrahydroquinoline Antimalarial Hit from the Medicines for Malaria Pathogen Box and Identification of its Mode of Resistance as PfeEF2

E. Winzeler, D. Fidock, F. Gamo, 2022, ChemMedChem.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

Richard D. Taylor, D. Goldberg, A. Cowman, 2022, Journal of medicinal chemistry.

Covalent macrocyclic proteasome inhibitors mitigate resistance in Plasmodium falciparum

H. Zhang, M. Bogyo, D. Fidock, 2023, bioRxiv.

Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets.

D. Fidock, A. Adibekian, D. Abegg, 2024, Cell chemical biology.

Mixed Alkyl/Aryl Phosphonates Identify Metabolic Serine Hydrolases as Antimalarial Targets

D. Fidock, F. Hackett, M. Blackman, 2024, bioRxiv.